目的 探討5-氟尿嘧啶(5-FU)和柳氮磺胺吡啶(sulfasalazine, SZ)對(duì)裸鼠皮下移植瘤胰腺癌細(xì)胞BxPC-3凋亡基因的作用。
方法 用RT-PCR和Western blot法分別檢測(cè)5-FU及SZ單獨(dú)或聯(lián)合作用后裸鼠皮下移植瘤凋亡相關(guān)基因NF-κB (p65)、bcl-2及cyclinD1 mRNA和蛋白表達(dá)水平以及Bax蛋白表達(dá)水平的變化。
結(jié)果 5-FU (7.5和15 mg/kg)和SZ(10和20 mg/kg)單獨(dú)或聯(lián)合作用裸鼠皮下移植瘤,其N(xiāo)F-κB (p65) mRNA表達(dá)相對(duì)含量和蛋白表達(dá)水平與各自對(duì)照組比較,除SZ組2個(gè)亞組外,其余各組均明顯降低(P<0.01); bcl-2和cyclinD1 在mRNA和蛋白水平以及Bax蛋白表達(dá)量與各自對(duì)照組比較差異均有統(tǒng)計(jì)學(xué)意義(P<0.01); 上述指標(biāo)經(jīng)多因素方差分析顯示二者間有明顯的交互作用。
結(jié)論 Bax水平上調(diào), bcl-2、cyclinD1及NF-κB (p65)水平下調(diào)可能是SZ可協(xié)同增強(qiáng)5-FU誘導(dǎo)裸鼠皮下移植瘤胰腺癌細(xì)胞BxPC-3凋亡的機(jī)理之一。
引用本文: 黃喆,郭克建,何三光. 柳氮磺胺吡啶和5-氟尿嘧啶對(duì)裸鼠皮下移植瘤胰腺癌細(xì)胞BxPC-3凋亡基因的影響. 中國(guó)普外基礎(chǔ)與臨床雜志, 2008, 15(8): 550-555. doi: 復(fù)制
1. | Verma M. Pancreatic cancer epidemiology [J]. Technol Cancer Res Treat, 2005; 4(3)∶295. |
2. | Saif MW, Sviglin H, Carpenter M. Impact of ethnicity on outcome in pancreatic carcinoma [J]. JOP, 2005; 6(3)∶246. |
3. | Hahn SA, Bartsch DK. Genetics of hereditary pancreatic carcinoma [J]. Clin Lab Med, 2005; 25(1)∶117. |
4. | Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells [J]. Clin Cancer Res, 1999; 5(1)∶119. |
5. | Wang CY, Mayo MW, Korneluk RG, et al. NF-κB antiapoptotis: induction of TRAF1 and TARF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation [J]. Science, 1998; 281(5383)∶1680. |
6. | Zong WX, Bash J, Gelinas C. Rel blocks both anti-Fas- and TNF-induced apoptosis and intact Rel transactivation domain is essential for this effect [J]. Cell Death Differ, 1998;5(11)∶963. |
7. | Jeremias I, Kupatt C, Baumann B, et al. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells [J]. Blood, 1998; 91(12)∶4624. |
8. | Wang CY, Cusack JC, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB [J]. Nat Med, 1999; 5(4)∶412. |
9. | Wolff R A, Chiao P, Lenzi R, et al. Current approaches and future strategies for pancreatic carcinoma [J]. Investigational New Drugs, 2000; 18(1)∶43. |
10. | Sharma J, Srinivasan R, Majumdar S, et al. BCL-XL protein levels determine apoptotic index in pancreatic carcinoma [J]. Pancreas, 2005; 30(4)∶337. |
11. | Brazdil J, Lukas Z, Hermanova M, et al. Apoptosis and expression of bcl-2 protein in invasive ductal adenocarcinoma of the pancreas [J]. Cesk Patol, 2003; 39(4)∶168. |
12. | 吳曉康, 吳育連, 鄭樟棟, 等. 胰腺癌細(xì)胞凋亡與bcl-2,bax基因表達(dá) [J]. 中國(guó)普通外科雜志, 2002; 11(3)∶171. |
13. | Kumar M , 劉正人, 田銳, 等. 生長(zhǎng)抑素受體2基因轉(zhuǎn)染抑制胰腺腫瘤細(xì)胞生長(zhǎng)機(jī)制的探討 [J]. 中華醫(yī)學(xué)雜志, 2004; 84(9)∶760. |
14. | 張?jiān)?夏曙霞, 錢(qián)家勤. Bax 基因表達(dá)在胰腺癌組織細(xì)胞凋亡作用 [J]. 肝膽外科雜志, 2002; 10(5)∶344. |
15. | Yip-Schneider MT, Nakshatri H, Sweeney CJ, et al. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells [J]. Mol Cancer Ther, 2005; 4(4)∶587. |
16. | Muerkoster S, Arlt A, Sipos B, et al. Increased expression of the E3-ubiquitin ligase receptor subunit beta TRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells [J]. Cancer Res, 2005; 65(4)∶1316. |
17. | Muerkoster S, Arlt A, Witt M, et al. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer [J]. Int J Cancer, 2003; 104(4)∶469. |
18. | Fahy BN, Schlieman M, Virudachalam S, et al. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2 [J]. Br J Cancer, 2003; 89(2)∶391. |
19. | Saleem M, Kaur S, Kweon MH, et al. Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway [J]. Carcinogenesis, 2005; 26(11)∶1956. |
20. | Schneider G, Weber A, Zechner U, et al. GADD45alpha is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability [J]. Int J Cancer, 2006; 118(10)∶2405. |
21. | Trauzold A, Schmiedel S, Roder C, et al. Multiple and synergistic deregulations of apoptosis controling genes in pancreatic carcinoma cells [J]. Br J Cancer, 2003; 89(2)∶1714. |
22. | Mouria M, Gukovskaya AS, Jung Y, et al. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis [J]. Int J Cancer, 2002; 98(5)∶761. |
- 1. Verma M. Pancreatic cancer epidemiology [J]. Technol Cancer Res Treat, 2005; 4(3)∶295.
- 2. Saif MW, Sviglin H, Carpenter M. Impact of ethnicity on outcome in pancreatic carcinoma [J]. JOP, 2005; 6(3)∶246.
- 3. Hahn SA, Bartsch DK. Genetics of hereditary pancreatic carcinoma [J]. Clin Lab Med, 2005; 25(1)∶117.
- 4. Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells [J]. Clin Cancer Res, 1999; 5(1)∶119.
- 5. Wang CY, Mayo MW, Korneluk RG, et al. NF-κB antiapoptotis: induction of TRAF1 and TARF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation [J]. Science, 1998; 281(5383)∶1680.
- 6. Zong WX, Bash J, Gelinas C. Rel blocks both anti-Fas- and TNF-induced apoptosis and intact Rel transactivation domain is essential for this effect [J]. Cell Death Differ, 1998;5(11)∶963.
- 7. Jeremias I, Kupatt C, Baumann B, et al. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells [J]. Blood, 1998; 91(12)∶4624.
- 8. Wang CY, Cusack JC, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB [J]. Nat Med, 1999; 5(4)∶412.
- 9. Wolff R A, Chiao P, Lenzi R, et al. Current approaches and future strategies for pancreatic carcinoma [J]. Investigational New Drugs, 2000; 18(1)∶43.
- 10. Sharma J, Srinivasan R, Majumdar S, et al. BCL-XL protein levels determine apoptotic index in pancreatic carcinoma [J]. Pancreas, 2005; 30(4)∶337.
- 11. Brazdil J, Lukas Z, Hermanova M, et al. Apoptosis and expression of bcl-2 protein in invasive ductal adenocarcinoma of the pancreas [J]. Cesk Patol, 2003; 39(4)∶168.
- 12. 吳曉康, 吳育連, 鄭樟棟, 等. 胰腺癌細(xì)胞凋亡與bcl-2,bax基因表達(dá) [J]. 中國(guó)普通外科雜志, 2002; 11(3)∶171.
- 13. Kumar M , 劉正人, 田銳, 等. 生長(zhǎng)抑素受體2基因轉(zhuǎn)染抑制胰腺腫瘤細(xì)胞生長(zhǎng)機(jī)制的探討 [J]. 中華醫(yī)學(xué)雜志, 2004; 84(9)∶760.
- 14. 張?jiān)?夏曙霞, 錢(qián)家勤. Bax 基因表達(dá)在胰腺癌組織細(xì)胞凋亡作用 [J]. 肝膽外科雜志, 2002; 10(5)∶344.
- 15. Yip-Schneider MT, Nakshatri H, Sweeney CJ, et al. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells [J]. Mol Cancer Ther, 2005; 4(4)∶587.
- 16. Muerkoster S, Arlt A, Sipos B, et al. Increased expression of the E3-ubiquitin ligase receptor subunit beta TRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells [J]. Cancer Res, 2005; 65(4)∶1316.
- 17. Muerkoster S, Arlt A, Witt M, et al. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer [J]. Int J Cancer, 2003; 104(4)∶469.
- 18. Fahy BN, Schlieman M, Virudachalam S, et al. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2 [J]. Br J Cancer, 2003; 89(2)∶391.
- 19. Saleem M, Kaur S, Kweon MH, et al. Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway [J]. Carcinogenesis, 2005; 26(11)∶1956.
- 20. Schneider G, Weber A, Zechner U, et al. GADD45alpha is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability [J]. Int J Cancer, 2006; 118(10)∶2405.
- 21. Trauzold A, Schmiedel S, Roder C, et al. Multiple and synergistic deregulations of apoptosis controling genes in pancreatic carcinoma cells [J]. Br J Cancer, 2003; 89(2)∶1714.
- 22. Mouria M, Gukovskaya AS, Jung Y, et al. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis [J]. Int J Cancer, 2002; 98(5)∶761.